Prism marketview biotech in motion spotlight: quoin receives fda clearance for netherton syndrome clinical optimization plan

New york, ny, december 13, 2023 – quoin pharmaceuticals (nasdaq:qnrx) has received u.s. food and drug administration (fda) clearance to implement several protocol amendments to its two ongoing clinical trials for qrx003, which is a potential treatment for netherton syndrome, a rare genetic skin disease for which there is no cure and no approved treatments.
QNRX Ratings Summary
QNRX Quant Ranking